Lite Strategy, Inc. (LITS): Revenue
$0
Year ended 2025-06-30
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-06-30 | $0 | -100.0% | 2025-09-26, From 2024-07-01 |
| 2024-06-30 | $65.30M | +33.8% | 2025-09-26, From 2023-07-01 |
| 2023-06-30 | $48.82M | +19.9% | 2024-09-19, From 2022-07-01 |
| 2022-06-30 | $40.70M | +17.0% | 2023-09-26, From 2021-07-01 |
| 2021-06-30 | $34.80M | +25.4% | 2022-09-08, From 2020-07-01 |
| 2020-06-30 | $27.76M | +464.7% | 2022-09-08, From 2019-07-01 |
| 2019-06-30 | $4.92M | +203.0% | 2022-05-23, From 2018-07-01 |
| 2018-06-30 | $1.62M | -93.0% | 2020-09-09, From 2017-07-01 |
| 2017-06-30 | $23.25M | n/a | 2019-08-28, From 2016-07-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | 2025-06-30 | $0 | -100.0% |
| Abbott Laboratories (ABT) | 2025-12-31 | $44.33B | +5.7% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $48.19B | -0.2% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $3.02M | +71.6% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $65.18B | +44.7% |
| Pfizer Inc (PFE) | 2025-12-31 | $62.58B | -1.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $94.19B | +6.0% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $480.14M | +5.7% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $65.01B | +1.3% |
Compare LITS, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗